SK Chemicals to Oversee Domestic Clinical Trials and Regulatory Approval
J2H Responsible for API Production and Quality Control

SK Chemicals is set to accelerate its open innovation efforts through a co-development partnership for new drug development with J2H Biotech (J2H).


On June 29, SK Chemicals announced that it had signed a letter of intent (LOI) for a strategic partnership with J2H, aiming for the domestic and international development and commercialization of the candidate treatment for metabolic dysfunction-associated steatohepatitis (MASH), 'J2H-1702.'


Hyunseon Park, Head of Business at SK Chemicals (right), and Giwon Jung, Vice President of J2H Biotech, are posing for a commemorative photo after signing a letter of intent for a strategic partnership to develop and commercialize the candidate drug for steatohepatitis, 'J2H-1702,' both domestically and internationally. SK Chemicals

Hyunseon Park, Head of Business at SK Chemicals (right), and Giwon Jung, Vice President of J2H Biotech, are posing for a commemorative photo after signing a letter of intent for a strategic partnership to develop and commercialize the candidate drug for steatohepatitis, 'J2H-1702,' both domestically and internationally. SK Chemicals

View original image

The two companies previously signed a memorandum of understanding (MOU) for the joint development of a new drug pipeline in March. Since then, SK Chemicals has conducted technical and business due diligence on J2H-1702, thoroughly reviewing the technology and commercial potential of the drug candidate and deciding to begin full-scale joint development.


J2H-1702 is an oral 11β-HSD1 inhibitor independently discovered and developed by J2H Biotech. 11β-HSD1 is an enzyme that regulates cortisol metabolism. J2H-1702 works by controlling excessive cortisol activity, thereby inhibiting fat accumulation, inflammation, and fibrosis progression during the course of MASH. J2H has completed phase 2a clinical trials of J2H-1702.


Under this agreement, the two companies plan to initiate detailed discussions on domestic and international clinical development and strategy, and to continue consultations to establish step-by-step development and commercialization plans.


Jae Sun Kim, CEO of J2H, said, "We expect that J2H-1702, developed with our proprietary technology, will accelerate its domestic and international development through collaboration with SK Chemicals. We will use this partnership as a stepping stone to demonstrate the value of J2H-1702 on the global stage."



Hyunseon Park, CEO of SK Chemicals, stated, "MASH is one of the most closely watched areas in new drug development, and through our due diligence, we have confirmed the competitiveness and scientific foundation of J2H-1702. Going forward, we will continue to expand our new drug pipeline by collaborating with companies that possess expertise and technological capabilities in disease areas where treatment options remain limited."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing